Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease. - Wikidata - awgldk - TriplyDB

Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease.

Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease.

http://www.wikidata.org/entity/Q50995559

about

The Role of Matrix Metalloproteinases in Diabetic Wound Healing in relation to Photobiomodulation Cell Therapy in Patients with Critical Limb Ischemia The effects of sulodexide on both clinical and molecular parameters in patients with mixed arterial and venous ulcers of lower limbs.Pharmacology in peripheral arterial disease: what the interventional radiologist needs to know.Adult vascular wall resident multipotent vascular stem cells, matrix metalloproteinases, and arterial aneurysms.Aterofisiol(®) in carotid plaque evolution Diabetic foot: surgical approach in emergency.The role of adult tissue-derived stem cells in chronic leg ulcers: a systematic review focused on tissue regeneration medicine.Skin grafting for the treatment of chronic leg ulcers - a systematic review in evidence-based medicine.Plasma MMP and TIMP evaluation in patients with deep venous thrombosis: could they have a predictive role in the development of post-thrombotic syndrome?Biomarkers in post-reperfusion syndrome after acute lower limb ischaemia.Spinal cord stimulation to achieve wound healing in a primary lower limb critical ischaemia referral centre.Cardiovascular disease prevention strategies for type 2 diabetes mellitus.Efficacy of cilostazol for the treatment of Raynaud's phenomenon in systemic sclerosis patients.PredyCLU: a prediction system for chronic leg ulcers based on fuzzy logic; part I - exploring the venous side.Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients.Effects of glucocorticoids and tumor necrosis factor-alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis.Skin tears and risk factors assessment: a systematic review on evidence-based medicine.Indicators of prognosis for admissions from a specialist diabetic foot clinic: a retrospective service improvement exercise.Venous aneurysm complicating arteriovenous fistula access and matrix metalloproteinases.Cell Based Therapeutic Approach in Vascular Surgery: Application and Review.

P2860

Q26744533-D9421759-4F61-4D1B-8946-D50D15069B70 Q26795443-710A7371-3BC5-4AAD-9C93-F1EEE60FE05B Q33632742-877D8798-70F8-473E-954D-3D4CB1D1AC71 Q34513880-758263CC-AB69-41F0-9423-C2FCB178C937 Q35239944-8F9BBCEE-BAC2-48C0-A496-46A7086A44DA Q35896394-696E6945-54B0-428C-9288-8A405FB9305C Q37292248-88EE765D-7476-4268-AF7C-27DB80493916 Q38591798-8E834684-E3E3-4569-ADBF-5E9813C9D325 Q38759995-8DEA1C70-14CF-4B9C-896B-C1C3285C78FF Q38960317-512FBBBA-1968-4D7E-A212-A10A06759937 Q39084806-C95261AF-0E59-4B85-8447-0562946674B4 Q39208811-E17649B6-B513-4DEF-B023-F7FD53A9DF2F Q39420208-458E69A4-1FEC-477D-AA52-F889C19DA2A9 Q40289594-863204FF-F257-4F7E-8D32-47E0D912FF57 Q41145547-85B86F59-B23F-4229-8932-EA790E3E3CB2 Q41985454-311A7A50-1C86-4F84-9C30-45D584414C9C Q42132165-294BCF65-BC6B-4FF7-880C-C88366223A2C Q47768853-64820449-740B-4F2E-9FC2-1A017EF3DBEA Q51181504-9B7C16EA-BD30-42B0-8588-E02A8E54226E Q54620721-B37F9D42-3DE3-41C6-BB44-9186092AF8D9 Q55346184-0A751154-D3D0-4105-BD29-8D9067B85510

P2860

Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease.

http://www.wikidata.org/entity/Q50995559

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease.

@en

Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease.

@nl

type

label

Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease.

@en

Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease.

@nl

prefLabel

Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease.

@en

Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease.

@nl

P1433

Q50995559-9EA762ED-EB96-4A42-A6F6-B782070A5A29

P1476

Q50995559-FE652D59-4DD9-4BBB-97D6-6BE54F1C1735

P2093

Q50995559-004105C5-B4DE-412E-9DA7-12466CC8920E

Q50995559-566C36E4-7B76-43AF-A13A-573435A00B6F

Q50995559-5865920E-D87E-4622-9BF1-CE569158A47A

Q50995559-676CC865-735C-4406-9A5A-C3593C8AC49F

Q50995559-7C7495CF-A76D-4A6A-AA9B-28681C3B44F3

P2860

Q50995559-02B3F70E-7CEB-488D-88D9-FA01BC2525D8

Q50995559-27EA72D4-5249-4021-A0A7-2EEC71A3D8A5

Q50995559-2A1CEBF1-3106-4809-9D03-63D10EAE3035

Q50995559-346EE7ED-6C48-4639-9431-FC2D7FADA3A1

Q50995559-5D2530E9-82D8-4C1B-8288-5A5312495355

Q50995559-6214106C-5B6F-46E2-8DF4-94B9C678502A

Q50995559-6932C800-40C6-4318-9FAE-07F315FA9646

Q50995559-99DBCD4A-7AA8-4750-82AE-BA190160896A

Q50995559-9B3E22A2-7E93-4587-AA3D-BC55652EF514

Q50995559-A600E1AA-B219-4A84-9AF6-0B4F3C21D474

P304

Q50995559-3CFDB05C-D9EE-45AE-9B2F-A9C58F406900

P31

Q50995559-93915EBC-2AFE-417F-90F2-9E8868E3E2B9

P356

Q50995559-2EF15665-8E98-4C1D-9208-E5B87E819954

P433

Q50995559-559E6F7F-A4BE-49C3-B2DA-4E49602C7ECE

P478

Q50995559-49978285-B226-41C4-AF5B-54039E975782

P50

Q50995559-AB4AF92D-AFD3-43D1-804C-C58C6AE4B316

Q50995559-E6E01688-D47C-4302-9ECB-923ECD17A432

Q50995559-FD30E426-C88E-4CD1-A4F4-4662E630E96E

P577

Q50995559-C89E5D67-7C37-4428-9026-16C7FD3E9FC5

P698

Q50995559-DBA87930-8FDE-402B-A7B7-65CC1FFBCDCF

P356

P1433

International Wound Journal

P1476

Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease.

@en

P2093

Domenico M Stillitano

http://www.w3.org/2001/XMLSchema#string

Luca Gallelli

http://www.w3.org/2001/XMLSchema#string

Luigi Battaglia

http://www.w3.org/2001/XMLSchema#string

Rossella Montemurro

http://www.w3.org/2001/XMLSchema#string

Vincenzo Molinari

http://www.w3.org/2001/XMLSchema#string

P2860

Diabetes care for patients with peripheral arterial disease

The US experience with cilostazol in treating intermittent claudication.

Cilostazol in diabetic neuropathy: premature farewell or new beginning?

Effects of statins and farnesyl transferase inhibitors on ERK phosphorylation, apoptosis and cell viability in non-small lung cancer cells.

Cilostazol inhibits matrix invasion and modulates the gene expressions of MMP-9 and TIMP-1 in PMA-differentiated THP-1 cells.

Increased ratio of serum matrix metalloproteinase-9 against TIMP-1 predicts poor wound healing in diabetic foot ulcers.

Doxycycline speeds up healing of chronic venous ulcers.

Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments.

Application of platelet-rich gel to enhance healing of transmetatarsal amputations in diabetic dysvascular patients.

Incidence, risk factors for amputation among patients with diabetic foot ulcer in a North Indian tertiary care hospital.

P304

250-253

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IWJ.12085

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Gianluca Buffone

Stefano de Franciscis

P577

2013-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23672237

http://www.w3.org/2001/XMLSchema#string